ArticlePloS one2024
Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Bedaquiline resistance: a predictable consequence of a game-changing drug?ASM case reports · 2026Article
- Rising bedaquiline resistance: exploring potential causes and next steps.The European respiratory journal · 2026Article
- Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis.BMJ global health · 2026Article
- Global research trends in BPaL and BPaLM regimens for drug-resistant tuberculosis: a bibliometric analysis.Tropical diseases, travel medicine and vaccines · 2025Article
- Alleviation of mycobacterial infection by impairing motility and biofilm formation via natural and synthetic molecules.World journal of microbiology & biotechnology · 2025Review
- Structural and mechanistic study of a novel inhibitor analogue ofnpj drug discovery · 2025Article
- Optimising TB investments in Belarus, Moldova, Kyrgyz Republic, Tajikistan and Uzbekistan: An allocative efficiency analysis.PLOS global public health · 2025Article
- Article
- Article
- Refined understanding of the impact of theMicrobiology spectrum · 2024Article
- Correction: Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026.PloS one · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 10 institutions in 10 countries.
Funding
Abstract
backgroundThe WHO has issued a call to action urging countries to accelerate the rollout of new WHO-recommended shorter all-oral treatment regimens for drug-resistant TB (DR-TB), which remains a public-health crisis. The all-oral, 6-month BPaL/M regimen comprises 3-4 drugs: pretomanid used in combination with bedaquiline and linezolid, with or without moxifloxacin. This regimen has been recommended by the WHO for use in DR-TB patients instead of ≥9-month (up to 24-month) regimens. This study aims to project this regimen's use, along with its components bedaquiline, pretomanid and linezolid, and other treatments for DR-TB globally through 2026. It is intended to guide global health stakeholders in planning and budgeting for DR-TB interventions. Projected usage could help estimate cost of the individual components of DR-TB regimens over time.
methodsSemi-structured interviews were conducted with national TB programme participants in key countries to gather intelligence on established plans and targets for use of various DR-TB treatment regimens from 2023 to 2026. These data informed development of projections for the global use of regimens and drugs.
resultsConsistent global growth in the use of shorter regimens in DR-TB treatment was shown: BPaLM reaching 126,792 patients, BPaL reaching 43,716 patients, and the 9-11-month all-oral bedaquiline-based regimen reaching 13,119 patients by 2026. By 2026, the longer all-oral regimen is projected to be used by 19,262 patients, and individualised treatment regimens by 15,344 patients.
conclusionThe study shows BPaL/M will be used in majority of DR-TB patients by 2024, reaching 78% by 2026. However, national efforts to scale-up, case-finding, monitoring, drug-susceptibility testing, and implementation of new treatments will be essential for ensuring they are accessible to all eligible patients in the coming years and goals for ending TB are met. There is an urgent need to engage communities in capacity building and demand generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.